Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:60597 |
Name | atypical chronic myeloid leukemia, BCR-ABL1 negative |
Definition | A myelodysplastic myeloproliferative neoplasm characterized by the principal involvement of the neutrophil series with leukocytosis and multilineage dysplasia. The neoplastic cells do not have a Philadelphia chromosome or the BCR/ABL fusion gene. |
Source | DiseaseOntology.org |
Alt Ids | DOID:8747 |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer bone marrow cancer myeloid neoplasm myelodysplastic/myeloproliferative neoplasm atypical chronic myeloid leukemia, BCR-ABL1 negative |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01787487 | Phase II | Azacitidine + Ruxolitinib | Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm | Recruiting | USA | 0 |
NCT03289910 | Phase II | Carboplatin + Topotecan + Veliparib Carboplatin + Topotecan | Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia | Active, not recruiting | USA | 0 |